RxDoctor Payments Data

Robert Schimenti, MD

Cardiovascular Disease · Moorestown, NJNPI 1326007428

Payments from drug & device makers

$3,672in general payments, 2019–2025

Across 244 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$674
  • Novartis$575
  • Boston Scientific$369
  • Johnson & Johnson$276
  • E.r. Squibb & Sons, L.L.C.$251
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$195
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,672100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,672 in reported general payments places this provider in the 55th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$360,666
Medicare patients
1,700
Services billed
4,685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban458$499,853
XareltoRivaroxaban172$205,543
EntrestoSacubitril/Valsartan102$95,354
FarxigaDapagliflozin Propanediol58$59,038
Repatha SureclickEvolocumab45$45,454
Praluent PenAlirocumab22$27,201
JardianceEmpagliflozin23$22,235
BrilintaTicagrelor37$18,870
Metoprolol Succinate838$11,040
Ranolazine ErRanolazine69$8,847
Dabigatran EtexilateDabigatran Etexilate Mesylate16$7,447
Atorvastatin Calcium646$6,433
Amiodarone Hcl39$4,888
Diltiazem 24hr Er (Cd)Diltiazem Hcl194$4,845
Ezetimibe180$4,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$151$499,853458 claims
Johnson & JohnsonXarelto$276$205,543172 claims
NovartisEntresto$575$95,354102 claims
AstraZenecaFarxiga, Brilinta$94$77,90895 claims
Boehringer IngelheimJardiance$118$22,23523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Moorestown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →